Results pending
Immune reconstitution (cladribine, alemtuzumab, aHSCT): reset the immune system for lasting remission in MS (type not specified)
MS (type not specified) · Immune reconstitution (cladribine, alemtuzumab, aHSCT)
Trials have finished, but some results have not been read yet. There is no verdict until they are, because one unread trial can change the answer.
- Trials
- 3
- Running now
- 0
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
No controlled trial has reported a result yet.
Other linked trials: 3
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 3
These linked trials do not set the status.
- CLADRI_NETStopped, other reason
Phase 4 · 2023 · Not randomised
- Hematopoietic Stem Cell Therapy for Inflammatory MSNo result found
Phase 2 · 2005 · Compared with dimethyl fumarate, fingolimod, natalizumab
- Hematopoietic Stem Cell Therapy for Patients With Multiple SclerosisStopped, other reason
Phase 1/2 · 2003 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Trials: 2 → 3
- 2026-10-27First listed as Results pending
Related hypotheses
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): reset the immune system for lasting remission in early MS (CIS or RIS)
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): reset the immune system for lasting remission in NMOSD
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): reset the immune system for lasting remission in primary progressive MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): reset the immune system for lasting remission in relapsing MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): reset the immune system for lasting remission in relapsing and progressive MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): reset the immune system for lasting remission in secondary progressive MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error